Open Access

Systemic immune‑inflammation index predicts a reduced risk of end‑stage renal disease in Chinese patients with myeloperoxidase‑anti‑neutrophil cytoplasmic antibody‑associated vasculitis: A retrospective observational study

  • Authors:
    • Jin-Biao Chen
    • Rong Tang
    • Yong Zhong
    • Ya-Ou Zhou
    • Xiaoxia Zuo
    • Hui Luo
    • Li Huang
    • Wei Lin
    • Ting Wu
    • Yingqiang Yang
    • Ting Meng
    • Zhou Xiao
    • Xiang Ao
    • Xiangcheng Xiao
    • Qiaoling Zhou
    • Ping Xiao
  • View Affiliations

  • Published online on: July 13, 2021     https://doi.org/10.3892/etm.2021.10421
  • Article Number: 989
  • Copyright: © Chen et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Chronic inflammation has been indicated to be important in the pathogenesis of anti‑neutrophil cytoplasmic antibody‑associated vasculitis (AAV). The systemic immune‑inflammation index (SII) is a novel marker of inflammation. The present study was thus performed to explore the association between the SII at diagnosis and inflammatory response and disease activity in Chinese patients with myeloperoxidase (MPO)‑AAV. Furthermore, it was evaluated whether the SII is able to predict the progression to end‑stage renal disease (ESRD) and patient survival. A total of 190 patients with MPO‑AAV were included in the present study. The baseline SII was positively correlated with C‑reactive protein (CRP; r=0.274, P<0.0001) and the erythrocyte sedimentation rate (ESR; r=0.481, P<0.0001). However, the SII had no obvious correlation with the Birmingham vasculitis activity score. Patients with SII≥2,136.45 exhibited better cumulative renal survival rates than those with SII<2,136.45 (P=0.001). However, no significant difference in patient survival was indicated between patients with SII≥2,136.45 and those with SII<2,136.45 at diagnosis. In conclusion, the SII was positively correlated with CRP and ESR in Chinese patients with MPO‑AAV. Furthermore, the SII may be an independent factor associated with a reduced risk of ESRD.
View Figures
View References

Related Articles

Journal Cover

September-2021
Volume 22 Issue 3

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Chen J, Tang R, Zhong Y, Zhou Y, Zuo X, Luo H, Huang L, Lin W, Wu T, Yang Y, Yang Y, et al: Systemic immune‑inflammation index predicts a reduced risk of end‑stage renal disease in Chinese patients with myeloperoxidase‑anti‑neutrophil cytoplasmic antibody‑associated vasculitis: A retrospective observational study. Exp Ther Med 22: 989, 2021
APA
Chen, J., Tang, R., Zhong, Y., Zhou, Y., Zuo, X., Luo, H. ... Xiao, P. (2021). Systemic immune‑inflammation index predicts a reduced risk of end‑stage renal disease in Chinese patients with myeloperoxidase‑anti‑neutrophil cytoplasmic antibody‑associated vasculitis: A retrospective observational study. Experimental and Therapeutic Medicine, 22, 989. https://doi.org/10.3892/etm.2021.10421
MLA
Chen, J., Tang, R., Zhong, Y., Zhou, Y., Zuo, X., Luo, H., Huang, L., Lin, W., Wu, T., Yang, Y., Meng, T., Xiao, Z., Ao, X., Xiao, X., Zhou, Q., Xiao, P."Systemic immune‑inflammation index predicts a reduced risk of end‑stage renal disease in Chinese patients with myeloperoxidase‑anti‑neutrophil cytoplasmic antibody‑associated vasculitis: A retrospective observational study". Experimental and Therapeutic Medicine 22.3 (2021): 989.
Chicago
Chen, J., Tang, R., Zhong, Y., Zhou, Y., Zuo, X., Luo, H., Huang, L., Lin, W., Wu, T., Yang, Y., Meng, T., Xiao, Z., Ao, X., Xiao, X., Zhou, Q., Xiao, P."Systemic immune‑inflammation index predicts a reduced risk of end‑stage renal disease in Chinese patients with myeloperoxidase‑anti‑neutrophil cytoplasmic antibody‑associated vasculitis: A retrospective observational study". Experimental and Therapeutic Medicine 22, no. 3 (2021): 989. https://doi.org/10.3892/etm.2021.10421